These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Sarkar S; Raymick J; Imam S Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353 [TBL] [Abstract][Full Text] [Related]
3. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. During MJ; Kaplitt MG; Stern MB; Eidelberg D Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246 [TBL] [Abstract][Full Text] [Related]
5. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Albrecht S; Buerger E Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998 [TBL] [Abstract][Full Text] [Related]
6. Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. More SV; Choi DK Mol Neurodegener; 2015 Apr; 10():17. PubMed ID: 25888232 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism. Lee Y; Kim MS; Lee J Arch Pharm Res; 2017 Oct; 40(10):1117-1128. PubMed ID: 28952032 [TBL] [Abstract][Full Text] [Related]
8. Advances in drug development for Parkinson's disease: present status. Harikrishna Reddy D; Misra S; Medhi B Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413 [TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for Parkinson's disease: from bench to bedside. Tarazi FI; Sahli ZT; Wolny M; Mousa SA Pharmacol Ther; 2014 Nov; 144(2):123-33. PubMed ID: 24854598 [TBL] [Abstract][Full Text] [Related]
10. Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease. Miyazaki I; Asanuma M Curr Med Chem; 2016; 23(7):686-700. PubMed ID: 26795196 [TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 1/sphingosine-1-phosphate receptors dependent signalling in neurodegenerative diseases. The promising target for neuroprotection in Parkinson's disease. Motyl J; Strosznajder JB Pharmacol Rep; 2018 Oct; 70(5):1010-1014. PubMed ID: 30138818 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoids and Parkinson's disease. García-Arencibia M; García C; Fernández-Ruiz J CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):432-9. PubMed ID: 19839934 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease. Baul HS; Manikandan C; Sen D Brain Res Bull; 2019 Mar; 146():244-252. PubMed ID: 30664919 [TBL] [Abstract][Full Text] [Related]
15. Plant Polyphenols as Neuroprotective Agents in Parkinson's Disease Targeting Oxidative Stress. Hor SL; Teoh SL; Lim WL Curr Drug Targets; 2020; 21(5):458-476. PubMed ID: 31625473 [TBL] [Abstract][Full Text] [Related]
16. Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease. Ghanta MK; Elango P; L V K S B Curr Pharm Des; 2020; 26(37):4738-4746. PubMed ID: 32065086 [TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease: Mechanisms, translational models and management strategies. Raza C; Anjum R; Shakeel NUA Life Sci; 2019 Jun; 226():77-90. PubMed ID: 30980848 [TBL] [Abstract][Full Text] [Related]
18. Th17 cells: a promising therapeutic target for Parkinson's disease? Prots I; Winner B Expert Opin Ther Targets; 2019 Apr; 23(4):309-314. PubMed ID: 30871383 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Moors TE; Hoozemans JJ; Ingrassia A; Beccari T; Parnetti L; Chartier-Harlin MC; van de Berg WD Mol Neurodegener; 2017 Jan; 12(1):11. PubMed ID: 28122627 [TBL] [Abstract][Full Text] [Related]
20. Potassium channels: possible new therapeutic targets in Parkinson's disease. Wang Y; Yang PL; Tang JF; Lin JF; Cai XH; Wang XT; Zheng GQ Med Hypotheses; 2008 Oct; 71(4):546-50. PubMed ID: 18650029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]